Dermavita Company v EUIPO - Allergan Holdings France (JUVEDERM VYBRANCE) (EU trade mark - Judgment) [2021] EUECJ T-635/20 (06 October 2021)

Dermavita Company v EUIPO - Allergan Holdings France (JUVEDERM VYBRANCE) (EU trade mark - Judgment) [2021] EUECJ T-635/20 (06 October 2021)

The Board of Appeal correctly held it was not competent to grant an extension under Article 101(4); only the Executive Director may do so, and no such extension was made for the relevant period. The applicant did not apply for restitutio in integrum, which was the appropriate remedy for missing the time limit for...

Source-derived case information.

Citation
[2021] EUECJ T-635/20
Parties
Applicant: Dermavita Company S.a.r.l.; Respondent: Allergan Holdings France SAS; Respondent: European Union Intellectual Property Office (EUIPO)
Jurisdiction
European Union
Procedural Posture
EU Trade Mark Invalidity Appeal / Judgment on Appeal Against Board of Appeal Decision
Outcome
Action dismissed
Legal Topics
EU Trade Mark Law, Invalidity Proceedings, Procedural Time Limits, Exceptional Occurrences, Interruption of Proceedings, Restitutio in Integrum
Intellectual Property European Union Law EU Trade Mark Law Invalidity Proceedings Procedural Time Limits Exceptional Occurrences Interruption of Proceedings Restitutio in Integrum

Source-derived case record

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Downloadable case file Legal principles 4 Authorities cited 6 Party arguments 2 Amounts and remedies 1
Sign in to unlock

Parties

Dermavita Company S.a.r.l.

Applicant

Allergan Holdings France SAS

Respondent

European Union Intellectual Property Office (EUIPO)

Respondent

Procedural Posture

EU Trade Mark Invalidity Appeal / Judgment on Appeal Against Board of Appeal Decision

  1. 1 Whether the Board of Appeal erred in not granting an extension of time under Article 101(4) of Regulation 2017/1001 due to COVID-19 and capital controls
  2. 2 Whether the Board of Appeal erred in not interrupting proceedings under Article 106(1)(b) of Regulation 2017/1001 due to Lebanese capital controls

Ratio Decidendi

The Board of Appeal correctly held it was not competent to grant an extension under Article 101(4); only the Executive Director may do so, and no such extension was made for the relevant period. The applicant did not apply for restitutio in integrum, which was the appropriate remedy for missing the time limit for payment of the appeal fee. Article 106(1)(b) does not apply to applicants for invalidity, and general capital controls do not qualify as action against property. The action was therefore dismissed.

Court Disposition

Action dismissed

Orders

  • Dismisses the action
  • Orders Dermavita Company S.a.r.l. to pay the costs